NOVAVAX COVID-19 VACCINE WAS 90 PERCENT EFFECTIVE IN PHASE 3 US TRIAL

Highlights

• As per phase 3 trial which was conducted the US and Mexico, the vaccine had an overall efficacy of 90.4% in a group of 29,960 participants across 119 sites in the country

According to a report released by US-based company Novavax on the basis of ongoing phase 3 trial in the US and Mexico, its covid-19 vaccine was successful in showcasing an efficacy of 90%.

In a statement issued on Monday, Novava....